Login / Signup

Short-time interruption of second-line mycophenolate treatment in a patient with renal sarcoidosis enabled a marked antibody response to SARS-CoV-2 messenger RNA vaccine.

Peter SchnuelleSebastian KöllingAlexander MüllerWilhelm H Schmitt
Published in: Clinical kidney journal (2021)
Keyphrases
  • sars cov
  • case report
  • respiratory syndrome coronavirus
  • replacement therapy
  • coronavirus disease
  • nucleic acid